Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Howard L. Kaufman

Combination Immunotherapy for Melanoma

JAMA Oncology

Cancer Research

Oncology

2015

English

Efficacy and Safety of First-Line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma

English

Clinical Management of Multiple Melanoma Brain Metastases

English

Development of a New Fusion-Enhanced Oncolytic Immunotherapy Platform Based on Herpes Simplex Virus Type 1

Journal for ImmunoTherapy of Cancer

English

Updated Efficacy of Avelumab in Patients With Previously Treated Metastatic Merkel Cell Carcinoma After ≥1 Year of Follow-Up: JAVELIN Merkel 200, a Phase 2 Clinical Trial

Journal for ImmunoTherapy of Cancer

English

An Update on the Society for Immunotherapy of Cancer Consensus Statement on Tumor Immunotherapy for the Treatment of Cutaneous Melanoma: Version 2.0

Journal for ImmunoTherapy of Cancer

English

Perspectives in Immunotherapy: Meeting Report From the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy)

Journal for ImmunoTherapy of Cancer

English

Triple Threat to Cancer: Rationale for Combining Oncolytic Viruses, MEK Inhibitors, and Immune Checkpoint Blockade

English

Evaluation of Classical Clinical Endpoints as Surrogates for Overall Survival in Patients Treated With Immune Checkpoint Blockers: A Systematic Review and Meta-Analysis

Journal of Cancer Research and Clinical Oncology

English

Serum Vascular Endothelial Growth Factor and Fibronectin Predict Clinical Response to High-Dose Interleukin-2 Therapy

Journal of Clinical Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Howard L. Kaufman

Combination Immunotherapy for Melanoma

Efficacy and Safety of First-Line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma

Clinical Management of Multiple Melanoma Brain Metastases

Development of a New Fusion-Enhanced Oncolytic Immunotherapy Platform Based on Herpes Simplex Virus Type 1

Updated Efficacy of Avelumab in Patients With Previously Treated Metastatic Merkel Cell Carcinoma After ≥1 Year of Follow-Up: JAVELIN Merkel 200, a Phase 2 Clinical Trial

An Update on the Society for Immunotherapy of Cancer Consensus Statement on Tumor Immunotherapy for the Treatment of Cutaneous Melanoma: Version 2.0

Perspectives in Immunotherapy: Meeting Report From the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy)

Triple Threat to Cancer: Rationale for Combining Oncolytic Viruses, MEK Inhibitors, and Immune Checkpoint Blockade

Evaluation of Classical Clinical Endpoints as Surrogates for Overall Survival in Patients Treated With Immune Checkpoint Blockers: A Systematic Review and Meta-Analysis

Serum Vascular Endothelial Growth Factor and Fibronectin Predict Clinical Response to High-Dose Interleukin-2 Therapy